Article may be outdated

This article is 10 days old. Some details may have changed since publication.

The American Journal of Managed Care® (AJMC®)·4 min read·hard

Toxicity, Not Relapse, Drives Infant Soft Tissue Tumor Survival Gap

R
Rose McNulty
Toxicity, Not Relapse, Drives Infant Soft Tissue Tumor Survival Gap
✦AI Summary

A Canadian study reveals that infants under one year old have lower survival rates for soft tissue tumors compared to older children, primarily due to treatment-related toxicity rather than cancer relapse. The findings suggest a need for specialized care approaches for the youngest patients.

Why it matters

This research identifies a critical gap in pediatric oncology outcomes, pointing toward the need for less toxic treatment protocols for infants.

✦Dive DeeperCreate a free account to unlock

Infants younger than 1 year with bone and soft tissue tumors had poorer survival than children aged 1 to 10 years despite no greater risk of relapse, a gap largely explained by a 4-fold higher risk of treatment-related mortality (TRM), according to a Canadian population-based study published in Pediatric Blood & Cancer.1 After accounting for tumor type and metastases, infancy remained independently associated with worse overall survival (OS), with an adjusted HR of 1.61 (95% CI, 1.13-2.31; P = .009).

Infants also developed a different mix of tumors than older children. Malignant rhabdoid tumors (MRT) made up more than a quarter of infant cases vs less than 3% in older children.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in